| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 09/28/2005 | CN1673236A Prepn and application of heparin silver |
| 09/28/2005 | CN1672730A Acne eliminating skin care article and its prepn |
| 09/28/2005 | CN1672698A Externally applied medicine for treating dermatosis |
| 09/28/2005 | CN1672696A Plaster for treating burns and scalds |
| 09/28/2005 | CN1672688A Medical composite chitinamine gel |
| 09/28/2005 | CN1672686A Dispersive asiaticoside tablet and its prepn process |
| 09/28/2005 | CN1672676A Clamped beriberi treating medicated cotton |
| 09/28/2005 | CN1220683C Acyl derivatives for treating VLA-4 related disorders |
| 09/28/2005 | CN1220497C Antivirus antioxidizing active extract of proplis and its molecular clathrate compound preparation |
| 09/28/2005 | CN1220493C New application of lactose derivative |
| 09/28/2005 | CN1220492C External skin composition |
| 09/28/2005 | CN1220477C Pharmaceutical shampoo |
| 09/27/2005 | US6949646 Nitrogen compounds such as 2-Butyl-1-(2-methylpropyl)-1H-tetrazolo[1,5-a]imidazo[4,5-c][1,8]naphthyridine, used to induce biosynthesis of cytokines such as interferons and tumor necrosis factors, or for prophylaxis of viral diseases |
| 09/27/2005 | US6949643 Thiazolopytimidines and their use as modulators of chemokine receptor activity |
| 09/27/2005 | US6949585 Cytokine antagonist; immunology, viricides, antitumor agents, anticancer agents |
| 09/27/2005 | US6949580 Anticancer agents; restenosis; antiinflammatory agents; cardiovascular disorders |
| 09/27/2005 | US6949547 Antidiabetic agents; central nervous system disorders; cardiovascular disorders; hypotensive agents; anticancer agents |
| 09/27/2005 | US6949546 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity |
| 09/27/2005 | US6949544 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 09/27/2005 | US6949541 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof |
| 09/27/2005 | US6949535 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one |
| 09/27/2005 | US6949515 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases |
| 09/27/2005 | US6949510 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 09/27/2005 | US6949249 Mixture contains flow control agent and thickener |
| 09/26/2005 | WO2005110452A2 MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS |
| 09/26/2005 | CA2847331A1 Multiple-variable dose regimen for treating tnf.alpha.-related disorders |
| 09/26/2005 | CA2847142A1 Multiple-variable dose regimen for treating tnf.alpha.-related disorders |
| 09/26/2005 | CA2504868A1 Multiple-variable dose regimen for treating tnf.alpha. related disorders |
| 09/22/2005 | WO2005087786A1 Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same |
| 09/22/2005 | WO2005087775A1 Tricyclic heterocyclic compound and medicinal composition containing the compound as active ingredient |
| 09/22/2005 | WO2005087288A1 Medicinal preparation for angiogenesis |
| 09/22/2005 | WO2005087220A1 Antiwrinkling preparation |
| 09/22/2005 | WO2005087182A1 Functional powders |
| 09/22/2005 | WO2004064833A8 Clindamycin phosphate foam |
| 09/22/2005 | WO2003099270A8 Methods of treating allergic reactions |
| 09/22/2005 | US20050209343 Percutaneous absorption promoters and compositions for treating athlete's foot |
| 09/22/2005 | US20050209341 R-(-)-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane or its hydrochloride salt; inhibiting the uptake of norepinephrine and serotonin; antidepressants, analgesics; treating sleep disorders, autism, psychological disorders, eating disorders |
| 09/22/2005 | US20050209338 Phenethanolamine derivatives for treatment of respiratory diseases |
| 09/22/2005 | US20050209329 Potentiation of therapeutic effects of fatty acids |
| 09/22/2005 | US20050209325 Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
| 09/22/2005 | US20050209298 treating rheumatoid arthritis by photodynamic therapy (PDT), by administering an iminochlorin aspartic acid porphyrin derivative called ATX-S10 sodium salt; determining the location of a sentinel lymph node and the presence of cancer metastasis; compounds from US patent 6063777 |
| 09/22/2005 | US20050209267 Thioether substituted imidazoquinolines |
| 09/22/2005 | US20050209253 Corticotropin releasing factor (CRF) receptor antagonists; nervous system disorders, ischemia, gastrointestinal disorders, hypertension, eating disorders, sleep disorders; e.g. 2-(1-[7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperidin-2-yl)-ethanol |
| 09/22/2005 | US20050209252 Using an indazole compound |
| 09/22/2005 | US20050209240 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors |
| 09/22/2005 | US20050209230 2,4-Pyrimidinediamine compounds and their uses |
| 09/22/2005 | US20050209216 Inhibit the synthesis of TNF-alpha (TNF=tumor necrosis factor); use treating diseases linked to immune and inflammatory disorders or as analgesics; e.g. 7-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)quinoline |
| 09/22/2005 | US20050209214 1-oxa-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 09/22/2005 | US20050209201 allowing an ATP receptor antagonist ( Reactive Blue 2 ) to work on ATP receptors of cells to block them and thereby inhibit the release of inflammatory cytokines, particularly interleukin-6 (IL-6) and/or interleukin-8 (IL-8) |
| 09/22/2005 | US20050209192 Autoimmune disorders; modulating protein kinase C activity |
| 09/22/2005 | US20050209191 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 09/22/2005 | US20050209159 Effectors of dipeptidyl peptidase IV for topical use |
| 09/22/2005 | US20050209130 Compositions and methods for treatment of rosacea |
| 09/22/2005 | US20050208619 29 human secreted proteins |
| 09/22/2005 | US20050208525 Nucleotide sequences coding preferential polypeptide for use in the treatment defects in immune and inflammatory response |
| 09/22/2005 | US20050208129 Prolonged release bioadhesive therapeutic systems |
| 09/22/2005 | US20050208124 Drugs containing riboflavin-type compounds |
| 09/22/2005 | US20050208106 Composition containing oat straw and willow herb extract |
| 09/22/2005 | US20050208046 TWEAK receptor |
| 09/22/2005 | US20050208042 Inducing lack of responsiveness to an antigen in an individual having a transplanted organ, tissue, cell; administering an effective amount of a humanized antibody; one antigen binding region of nonhuman origin and a portion of an immunoglobulin heavy chain of human origin |
| 09/22/2005 | US20050208016 derivatives effectively block the inflammatory effects of RANTES, and are useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, and rheumatoid arthritis, hiv |
| 09/22/2005 | US20050208011 Hair follicle growth |
| 09/22/2005 | US20050208001 rosacea, intrinsic or chronological aging, pigmentation, seborrhoeic function, barrier function, epidermal lipid secretion, wound healing, atrophies, ulcers, immune system, cardiovascular system disorders; 6-(5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthalene-2-carbonyl)naphthalene-2-carboxylic acid |
| 09/22/2005 | DE102004009153A1 Use of ascorbic acid and/or its derivatives for increasing microcirculation and nutrient supply in skin includes use in cosmetics and dermatics, e.g. emulsion or mousse for skin or face, day or night cream or lotion |
| 09/22/2005 | DE102004009150A1 Use of ascorbic acid and/or its derivatives for cleansing and/or reducing size of skin pores includes use in cosmetics and dermatics, e.g. emulsion or mousse for skin or face, day or night cream or lotion |
| 09/22/2005 | DE10152351B4 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat Solid pharmaceutical formulation for a Piperazinharnstoffderivat |
| 09/22/2005 | CA2559377A1 Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same |
| 09/21/2005 | EP1577383A1 Novel adaptor protein binding to mammalian toll-like receptor 3 and gene thereof |
| 09/21/2005 | EP1577299A1 Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient |
| 09/21/2005 | EP1576969A1 A wound care device |
| 09/21/2005 | EP1576368A2 Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation |
| 09/21/2005 | EP1576168A2 Therapeutic polypeptides nucleic acids encoding same and methods of use |
| 09/21/2005 | EP1576160A2 Borrelidin-producing polyketide synthase and its use |
| 09/21/2005 | EP1576088A2 Dominant negative proteins and methods thereof |
| 09/21/2005 | EP1576086A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 09/21/2005 | EP1575984A2 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade |
| 09/21/2005 | EP1575964A2 N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| 09/21/2005 | EP1575954A2 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 09/21/2005 | EP1575942A1 Novel compounds having selective inhibiting efect at gsk3 |
| 09/21/2005 | EP1575939A1 Novel compounds having selective inhibiting effect at gsk3 |
| 09/21/2005 | EP1575938A1 Novel compounds having selective inhibiting effect at gsk3 |
| 09/21/2005 | EP1575617A1 Use of topical pharmaceutical compositions comprising an active agent and permeation-enhancing base for the manufacture of a medicament to treat various forms of inflammatory dermatosis |
| 09/21/2005 | EP1575605A1 Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser |
| 09/21/2005 | EP1575600A1 Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations |
| 09/21/2005 | EP1575598A1 Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate |
| 09/21/2005 | EP1575585A1 Pharmaceutical liquid composition containing pyridone derivative |
| 09/21/2005 | EP1575552A2 Metal-containing materials, compositions and methods |
| 09/21/2005 | EP1575544A1 Use of an alkyl ether of hydroxystilbene for the treatment of dry skin |
| 09/21/2005 | EP1575533A2 Topical compositions having a natural ingredient and method of use |
| 09/21/2005 | EP1575524A2 Proliferated cell lines and uses thereof |
| 09/21/2005 | EP1575521A2 Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof |
| 09/21/2005 | EP1575499A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 09/21/2005 | EP1575497A2 Novel composition and methods for the treatment of psoriasis |
| 09/21/2005 | EP1575480A2 Compositions and methods for the treatment of immune related diseases |
| 09/21/2005 | EP1377560B1 Piperazine derivatives as tachykinin antagonists |
| 09/21/2005 | EP1303501B1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 09/21/2005 | EP1282602B1 Propanoic acid derivatives as integrin receptor antagonists |
| 09/21/2005 | EP1220857B1 Gonadotropin releasing hormone receptor antagonists and their related methods of use |
| 09/21/2005 | EP1140091B1 Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia |
| 09/21/2005 | EP1098630B1 Composition for enhancing epidermal lipid production |